Wilms' tumour (WT) has a diverse and complex molecular aetiology, with several different loci identified by cytogenetic and molecular analyses. One such locus is on chromosome 7p, where cytogenetic abnormalities and loss of heterozygosity (LOH) indicate the presence of a Wilms' tumour suppressor gene. In order to isolate a candidate gene for this locus, we have characterized the breakpoint regions at a novel constitutional chromosome translocation (t(1;7)(q42;p15)), found in a child with WT and skeletal abnormalities. We identified two genes that were interrupted by the translocation: the parathyroid hormone-responsive B1 gene (PTH-B1) at 7p and obscurin at 1q. With no evidence for LOH at 1q42, we focused on the characterization of PTH-B1. We detected novel alternately spliced isoforms of PTH-B1, which were expressed in a wide range of adult and foetal tissues. Importantly, expression of two isoforms were disrupted in the WT of the t(1;7) patient. We also identified an additional splice isoform expressed only in 7p LOH tumours. The disruption of PTH-B1 by the t(1;7), together with aberrant splicing in sporadic WTs, suggests that PTH-B1 is a candidate for the 7p Wilms' tumour suppressor gene.
Introduction
Wilms' tumour (WT) is the most common paediatric malignancy of the kidney. It has a diverse and complex molecular aetiology, with several different loci identified by cytogenetic and molecular analyses, although only one gene (WT1) has so far been cloned (Gessler et al., 1990; Brown and Malik, 2001) . However, WT1 is only mutated in approximately 20% of all WTs and this suggests the involvement of other genetic loci in the development of WT (Brown and Malik, 2001 ). Investigations of inherited predisposition syndromes and loss of heterozygosity (LOH) studies in sporadic tumours have identified several additional loci, including 11p15 (designated WT2) (Henry et al., 1989; Koufos et al., 1989; Ping et al., 1989; Reeve et al., 1989) , 1p (Grundy et al., 1994) , 7p (Wilmore et al., 1994; Miozzo et al., 1996; Grundy et al., 1998; Powlesland et al., 2000; Perotti et al., 2001) , 11q (Radice et al., 1995) and 16q (Grundy et al., 1994) .
Most of the above changes, apart from those at 11p, are thought to be involved in the progression of the disease rather than the initiating event in WT development. However, chromosome 7p deletions, 7q duplications, or a combination of these two events have been observed in a large subset of WTs (15-25%) occurring as a result of acquired rearrangements, that is, deletions, translocations and long-arm isochromosomes (reviewed in Rivera, 1995) . Since some of these occur as the sole cytogenetic abnormality, this implies that chromosome 7 aberrations can occur as a primary event in WT development.
We therefore became interested in one patient (WT21) who developed WT, with a nephrogenic rest in the contralateral kidney. This bilateral disease suggested a genetic predisposition to WT and importantly, the patient did not have a WT1 mutation (Brown et al., 1993; Powlesland et al., 2000) , but did have a novel constitutional balanced chromosome translocation; t(1;7)(q42;p15) (Hewitt et al., 1991) . In addition to WT, this patient had congenital skeletal abnormalities similar to the thrombocytopenia and absent radii (TAR) syndrome, a disease not previously associated with WT. Our past data showed that the WT in this patient (WT21) was monosomic for 7p and trisomic for 7q, because of the presence of an isochromosome 7(q) and the retention of both translocated chromosomes (Wilmore et al., 1994) . We also previously localized the breakpoint on 7p between STS markers sWSS355 and sWSS1449 (Reynolds et al., 1996) and showed that 9% of sporadic WTs had LOH in a region encompassing this breakpoint (Powlesland et al., 2000) . Other groups have shown similar findings for 7p LOH, with the minimal regions of LOH overlapping 7p15 (Miozzo et al., 1996; Grundy et al., 1998) . Taken together, these data suggest the presence of a tumour suppressor gene on 7p15. The work presented in this paper describes the cloning and characterization of the constitutional t(1;7)(q42;p15) breakpoints found in patient WT21, and the identification of a gene at 7p not previously associated with WT, which is disrupted in the WT of the translocation patient.
Results

Fine mapping of the t(1;7) breakpoint
We previously used FISH mapping to localize the 7p breakpoint of the constitutional t(1;7)(q42;p15) in patient WT21 to within a 440 kb YAC (yWSS1081) on 7p15, in-between STS markers sWSS355 and sWSS1449 (Reynolds et al., 1996) . We used this YAC to screen a chromosome 7 cosmid library and isolated 27 positive cosmid clones. These clones were grouped (A-C) relative to an overlapping YAC, yWSS3805, and markers sWSS355 and sWSS1449 ( Figure 1a ). FISH mapping of representative cosmids from each group allowed their positioning relative to the breakpoint (data not shown). Three cosmids from group A were localized as proximal (1D10), distal (2A05) or spanning (2G01) the breakpoint, thus identifying cosmid 2G01 as containing the 7p breakpoint region.
A standard restriction mapping approach was used to identify smaller fragments of cosmid 2G01 that contained the breakpoint. These fragments were subcloned, 32 P-dCTP labelled and used to probe a Southern blot of WT21 constitutional DNA and normal control DNA in order to (a) verify single copy probes, (b) identify the fragment spanning the breakpoint and (c) exclude rearrangements of 2G01 (Figure 1b) . A 0.58 kb SacI/ EcoRI (E500) fragment of 2G01 hybridized to abnormal junction fragments in WT21 constitutional DNA. BLAST analysis with the E500 sequence localized the breakpoint within the chromosome 7p BAC contig djs94 (B180 kb, Genbank Accession number: AC008080). Database scanning showed no known exons within the E500 fragment and exon trapping of 2G01 did not reveal any robust candidate genes. Rapid amplification of cDNA ends (RACE) and cDNA library screens using trapped exons were also unsuccessful in identifying candidate genes.
To identify the precise location of the breakpoint on both 1q and 7p, a subgenomic library (average insert size 15-23 kb) was constructed using WT21 constitutional DNA and probed with E500. Two independent E500-hybridizing clones were selected (Figure 2a : T4-1, T1-2) and Southern blotted (again with the E500 probe). Fragments of 3 and 4 kb were identified (arrowed in Figure 2a ), subcloned, sequenced and found to contain the breakpoint in the same orientation (Figure 2b : partial sequence shown). The reciprocal abnormal junction fragment was isolated by PCR using primers specific for chromosomes 1 and 7 that flanked the breakpoint. Sequencing of both 1 : 7 and 7 : 1 fragments revealed a minor 2 bp 'GA' deletion at their junctions (Figure 2b : boxed). The breakpoint was precisely mapped by alignment with the draft human genome sequence to 7p14.3 (at position 126 575 bp of AC008080) and 1q42.13 (at 90 455 bp of AL359510). PCR analysis of WT21 normal kidney DNA (Figure 2c : first lane) and LCL DNA (second lane) confirmed the presence of both the translocated derivative chromosomes (panels i and ii), normal copies of chromosome 7 (panel iii) and chromosome 1 (panel iv). The loss of the remaining normal copy of 7p within the tumour of WT21 was also confirmed by PCR analysis (Figure 2c , panel iii, third Two genes are interrupted by the t(1;7) breakpoint
The sequences flanking the breakpoints were analysed using BLAST and NIX search programmes (http:// www.hgmp.mrc.ac.uk/). Chromosome 1q analysis revealed that the breakpoint bisected the first intron of the obscurin gene (AJ002535). Obscurin encodes a sarcomeric Rho guanine nucleotide exchange factor (GEF) involved in sarcomere assembly (Young et al., 2001) . However, alterations in this this gene was not pursued further, because our previous studies did not detect any LOH at 1q in the WT of patient WT21 or in other sporadic WTs (Wilmore et al., 1994) . Chromosome 7p database searches revealed three ESTs (B22 kb from the breakpoint) derived from independent cDNA libraries, which were found to be homologous to the parathyroid hormone-responsive B1 (PTH-B1) gene (NM_014451). PTH-B1 was originally identified in osteoblastic SaoS-2/B10 cells, where expression was rapidly downregulated (within 1 h) in response to parathyroid hormone (PTH) (Adams et al., 1999) . The gene product(s) of PTH-B1 bear no strong homology to any other known proteins or protein domains. These ESTs represent two previously uncharacterized alternative splice isoforms of PTH-B1 and we have also subsequently cloned three additional isoforms by RT-PCR from foetal kidney RNA, making six possible PTH-BI isoforms in total (Figure 3b and c). In total, there appear to be 24 exons of the PTH-B1 gene, extending over approximately 700 kbp of genomic DNA ( Figure 3a ). Our mapping of the t(1;7) breakpoint on 7p places it in intron 22 of the gene (Figure 3a ), thus interrupting PTH-B1 by translocating exons 1-22 and 23-24 to different derivative chromosomes.
Isoforms 2-6 differ relative to the original published PTH-B1 sequence (NM_014451; referred to here as isoform 1) at two positions (1367 and 2456 bp; Figure 4 ). At 1367 bp (Figure 4a ), isoforms 2, 3 and 4 contain two additional exons (13 and 14) that code for 40 amino acids, 13 of which (within exon 13) are capable of being phosphorylated (Figure 4a : bold). In addition, isoform 4 has an unspliced intron at this location (intron 12) that precedes exon 13. This intron codes for four additional amino acids, which are followed by an in-frame termination codon, presumably leading to the production of a truncated PTH-B1 protein. Isoform 5 has only exon 14 inserted at 1367 bp, which gives an in-frame insertion of extra five amino acids.
At 2456 bp ( Figure 4b ) isoforms 2, 5 and 6 have completely different C-terminal ends from isoform 1. Isoform 2 contains an unspliced intron (intron 21) that codes for 10 alternative C-terminal amino acids followed by a termination codon (Figure 4b ). In isoform 5, exon 22 has been replaced with exons 23 and 24, which code for different 38 amino acids at the C-terminus. Sequence analysis shows that exon 23 is part of a mammalian apparent long terminal repeat retrotransposon (MaLR) that is approximately 342 bp in length (Smit, 1993) . Isoform 6 has exon 22 replaced by exon 24 alone, leading to the deletion of 10 amino acids from the Cterminus, because the first codon in exon 24 is a stop codon (Figure 4b ).
The two unspliced introns (12 and 21) were found in large cDNA clones or PCR products in which they were flanked by normally spliced exons, demonstrating that these unspliced introns were not artefacts caused by genomic DNA contamination.
Both exons 23 and 24 map to the other side of the WT21 breakpoint from exons 1-22. Thus the t(1;7) breakpoint on 7p is predicted to interrupt isoforms 5 and 6 of PTH-B1. The derivative translocation (a) Southern blot of two representative phage clones (T4-1/T1-2) isolated from a sub-genomic WT21 LCL library. The E500 2G01 fragment (used as a probe) identified 3 and 4 kb inserts (arrowed), which were found to contain the breakpoint in the same orientation; (b) partial sequence of the t(7;1) translocation breakpoint isolated from the subgenomic library. Boxed 'GA' indicates precise position of breakpoint. (c) PCR confirmation of the breakpoint in WT21. All panels contain the same genomic DNA templates, and show PCR products for (i) t(7;1) and (ii) t(1;7) derivative chromosomes, (iii) normal copies of chromosome 7 (shaded boxes) and (iv) chromosome 1 (white boxes). WT21 is the t(1;7) translocation patient, WT77 is a WT patient without 7p LOH. NK ¼ normal kidney, LCL ¼ lymphoblastoid cell line, WT ¼ Wilms' tumour 1;7 translocation and Wilms tumour EG Vernon et al chromosomes are not predicted to result in any aberrant gene fusions, because in the translocation chromosomes the obscurin and PTH-B1 genes are transcribed in opposite directions.
PTH-B1 isoforms are ubiquitously expressed in many adult and foetal tissues, apart from WT21 Wilms' tumour Some of the PTH-B1 splice isoforms can be distinguished by RT-PCR analysis using primers specific for their 3 0 ends ( Figure 5 ). Primer pair pFOR5I (in exon 19) and NR3 (in exon 22) were used to differentiate between the isoform containing unspliced intron 21 (isoform 2) and those that do not (isoforms 1, 3 and 4).
Primer pair pFOR5I and 2230109F (in exon 24) were used to identify isoforms 5 (with exon 23) and 6 (without exon 23). All these isoforms were expressed in a wide variety of adult and foetal tissues, apart from placenta where isoforms 1-4 were not expressed and adult liver where isoform 5 was not expressed (Figure 5) .
RT-PCR analysis was performed on 13 WTs (seven of which had 7p LOH) using primer pairs F3INT (in exon 20) and NR3 (in exon 22) for isoforms 1-4, and F3INT and 2230109F (in exon 24) for isoforms 5 and 6 (Figure 6 ). Apart from three WTs, all isoforms were expressed in every case. In WT21 there was no expression of isoforms 5 and 6 (Figure 6a , lane 2), as predicted from the interruption of the PTH-B1 gene by These intraexonic splices appear to result in a 48 base (16 amino acids) in-frame deletion within exon 21 (Figure 7b ). There was no evidence of any genomic deletion in this region in WT42 or 82 (Figure 7a , ii). In addition, multiple novel bands were also observed in one 7p LOH WT, which hybridized to isoform 5-specific probes (indicated by asterisks in Figure 6b , WT42).
Tumour histology data were available for six of the samples shown in Figure 6b . Of these, WT42, 59 and 73 were blastemal predominant, whereas WT30, 57 and 82 were triphasic. Thus, the two tumours with aberrant splicing (WT42 and 82) had different histology, suggesting that this splicing was not merely a reflection of the pattern of differentiation in the tumours.
In total, therefore, three out of nine 7p LOH tumours showed changes in PTH-B1 expression. Thus, in addition to the PTH-B1 gene being interrupted by the WT21 translocation, two other WTs (42 and 82) also displayed aberrant splicing of PTH-B1. 
Discussion
The work in this paper set out to characterize the areas surrounding the translocation breakpoints found in WT patient WT21, in an attempt to identify novel genes on 7p involved in WT. This region had been implicated in WT development by our previous studies (Wilmore et al., 1994; Reynolds et al., 1996; Powlesland et al., 2000) as well as the work of other groups (Miozzo et al., 1996; Grundy et al., 1998) .
Cloning and sequencing of the WT21 breakpoint allowed exact positioning of the t(1;7) breakpoints of WT21 to 1q42.13 between markers SHGC-76460 and SHGC-146605, and to 7p14.3 between STS-T78597 and SHGC-172305. Two genes are interrupted by the breakpoints: the obscurin gene at 1q42 and the parathyroid hormone-responsive B1 gene (PTH-B1) at 7p14.
Obscurin was originally identified in a yeast 2-hybrid screen as an interacting partner of the scaffolding protein titin (Young et al., 2001) . However, obscurin is unlikely to be a candidate for a WT suppressor gene because (a) we did not detect any LOH of 1q in our WTs and (b) the WT of WT21 retains both copies of 1q (Wilmore et al., 1994) . It is possible that the disruption of one copy of obscurin may contribute to the TAR-like symptoms observed in this patient. Further work is required to elucidate the role of obscurin in this patient and in others with similar skeletal abnormalities.
Our efforts to identify other potential candidates involved in WT genesis were therefore focused on a cluster of chromosome 7 ESTs that locate near the WT21 7p breakpoint. These were found to possess a 99% sequence identity to the PTH-B1 gene (Adams et al., 1999) . Our analyses show that the PTH-B1 gene is multiply spliced in kidney as well as in many other adult and foetal tissues. We have also demonstrated that both isoforms 5 and 6 are disrupted by the t(1;7) constitutional breakpoint of WT21, and therefore not expressed in the WT of WT21. Although these isoforms are expressed in other 7p LOH WTs, additional tumourspecific isoforms appear to be present in two other WTs (WT42 and 82). In this subset of WT patients, we showed mutually exclusive expression of isoform 2 and a novel isoform with an intraexonic splice in exon 21. The splicing alterations were tumour-specific (i.e. not germ line) and neither patient had any congenital abnormalities, unlike patient WT21 in which PTH-B1 was interrupted by a germline chromosomal defect. This is the first report of the expression patterns of new isoforms of the PTH-B1 gene and their aberrant expression in cancer.
While the function of PTH-B1 gene has yet to be elucidated, it is thought to encode for a globular protein that may be involved in intracellular signalling (Adams et al., 1999) . Our amino-acid comparisons of the PTH-B1 alternative transcripts detailed in this paper suggest that each protein isoform could have distinct cellular roles, possibly within different sub-cellular compartments. The splicing defects that we have demonstrated in two 7p LOH WTs could therefore affect certain specific cellular functions of PTH-B1. Changes in relative levels of alternative spliced isoforms that affect tumorigenesis are not uncommon (Nissim-Rafinia and Kerem, 2002) and include changes in the relative levels of WT1 isoforms in WT (Baudry et al., 2000) .
Interestingly, WT patients with associated hypercalcaemia have elevated PTH levels, and removal of the tumour resets normal cellular levels (de Kraker and Voute, 1979) . We have shown that PTH-B1 is ubiquitously expressed and it is known that PTH can rapidly decrease the expression of PTH-B1 (Adams et al., 1999) . Thus high levels of PTH associated with hypercalcaemia in WT patients could affect the expression of PTH-B1 and might contribute to the tumour phenotype in some cases. One could speculate that the constitutional disruption of isoforms 5 and 6 in patient WT21 may be involved in their skeletal abnormalities, because PTH-B1 is thought to be important in PTH effects on osteoblasts (Adams et al., 1999) . The loss of the second copy of PTH-B1 in the developing kidney of patient WT21 could then have resulted in WT. A precedent for this is seen with WAGR patients, where the loss of one functional copy of WT1 results in the development of a particular phenotype (i.e. genitourinary abnormalities), while loss of the remaining copy of WT1 results in WT. However, it is important to note that most, but not all, WTs of WAGR patients show somatic mutation in the remaining WT1 copy, suggesting the involvement of other genes yet to be , 1997) . At least two other loci on 7p (7p13-14 and 7p22) identified by different groups appear to be the target for chromosomal rearrangements or deletions in WTs (Sawyer et al., 1993; Rivera, 1995; Grundy et al., 1998; Lobbert et al., 1998; Perotti et al., 2001) . It is possible, therefore, that there are multiple genes on 7p, any one of which can predispose to WT development. Alternatively, haploinsufficiency of several genes on 7p might collectively contribute to WT development. Finding the critical gene(s) may therefore necessitate the use of complementary methods, such as the use of animal models (Balmain, 2002) .
Materials and methods
Tissue samples
Fresh normal kidney and WT tissues were snap frozen in liquid nitrogen and then stored at À701C. DNA and RNA were extracted from frozen tissues using standard methods. One patient (WT21) had a constitutional t(1;7) with skeletal abnormalities (Hewitt et al., 1991) . All other cases were sporadic with no obvious genetic predisposition or congenital defects. The 7p LOH status of these samples has been determined previously (Powlesland et al., 2000) .
Cell culture WT21 lymphoblastoid cell line (LCL) and cultured WT cells were maintained as previously described (Brown et al., 1989; Wilmore et al., 1994; Reynolds et al., 1996) . Characterization of cultured WT cells by LOH and cytogenetic analysis have shown that these cells are tumour-derived (Brown et al., 1989; Wilmore et al., 1994) .
Southern blotting and identification of a 0.5 kb 2G01 breakpoint fragment Genomic DNA was extracted from normal kidney tissue and WT21 LCL cells (as previously described in Sambrook et al., 1989) and 5 mg was digested with KpnI, PvuII or SacI (24 h, 371C). The resulting fragments were separated on a 0.6% agarose gel and transferred onto Hybond-N + . This filter was prehybridized (7% SDS, 5 mg/ml Bovine Serum Albumin (Sigma), 0.5 m NaOPO 4 pH7.2, 1 mm EDTA) for 3 h at 651C, then hybridized with the relevant probe for 18 h at 651C (Figure 1 ). Probes were generated by digesting 2G01 cosmid DNA with various restriction enzymes (SacI, HindIII, XbaI, EcoRI). These fragments were separated on a 0.6% gel, some of which were gel-extracted, 32 P-dCTP labelled and purified (Amersham Pharmacia Biotech's Multiprime labelling DNA kit and Nickt columns, respectively). These fragments were also subcloned into puc18.
Chromosome 1:7 breakpoint genomic cloning WT21 LCL genomic DNA (100 mg) was partially digested with 2.4 U Sau3A (New England Biolabs) and subsequently size fractionated on a 12 ml 10-40% sucrose density gradient (Wilson and Goulding, 1986) for 21 h at 78 900 g. Fractions containing WT21 LCL DNA fragments within a 15-23 kb range were pooled, dialysed, precipitated (Sambrook et al., 1989) and resuspended in 10 ml distilled H 2 O.
Size-fractionated inserts were ligated and packaged using Stratagene's Lambda DASHII/BamHI vector system, according to the manufacturer's instructions. The resulting library was titered and plated to a density of 50 000 PFU (plaque forming units)/15 cm 3 agar plate (4 Â 10 5 PFU total). Plaque lifts were performed on these plates using Schleicher & Schuell Optitran (0.45 mm) membranes as previously described (Benton and Davis, 1977) . Standard conditions were used (see above) to pre-hybridize/hybridize the filters and a 32 P-dCTPlabelled E500 DNA fragment (SacI/EcoRI fragment from 2G01) used as a probe. From these filters eight individual clones were isolated. In each case, the phage was eluted from the agar plugs (Sambrook et al., 1989) and taken through secondary and tertiary screens.
Phage DNA minipreps were performed on individual clones (Sambrook et al., 1989) and the resulting plasmid DNA was digested using a number of enzymes. Fragments were separated on a 0.8% agarose gel and Southern blotted using E500 as a probe. Two positive SacI/XbaI fragments (approx. 4 and 3 kb, respectively. Figure 2a) were identified, cloned into puc18 and positive clones sequenced (Figure 2b . Durham University sequencing service). Reciprocal inserts were obtained by PCR using 100 ng WT21 genomic DNA, 1 mm of primers (unless otherwise stated) BP1FA (chromosome 1 0 , positioned at 90 770 bp within AL359510) and E500-S1 (chromosome 7 forward primer: 5 0 -GAGGTCTGGT-CACTTGGAAAAT-3 0 , positioned at 126 747 bp within AC008080), 0.2 mm dNTPs (Amersham Pharmacia Biotech), 1 Â Supertaq buffer and 0.1 U Supertaq enzyme (HT Biotechnologies). PCR cycling parameters were as follows: 941C for 5 min; 35 cycles of 941C for 30 s, 581C for 30 s, 721C for 1 min and 721C for 5 min. In addition, PCRs were also carried out to check WT21 LCL for normal copies of chromosome 1 (BP1FA and BP1RA: 5 0 -GCTCGGCCTGTTTCTTCATC-3 0 ), chromosome 7 (E500-S1 and S13-1A: 5 0 -AAGGCATG-CAAAATGGAACTGC-3 0 ), t(7;1) (S13-1A and BP1RA) and the t(1;7) fragment (BP1FA and E500-S1).
RNA extraction and RT-PCR
Total RNA was obtained using the TRI REAGENTt protocol (Sigma), and reverse transcription was performed using the Moloney murine leukaemia virus reverse transcriptase, RNase H minus point mutant (M-MLV RT [H À ]: Promega). Each RT reaction was set up in a total of 25 ml according to the manufacturer's instructions using 0.5 mg of total RNA, 0.5 ml of ribonuclease inhibitor (30 000-50 000 U/ ml: Sigma) and 500 ng of Oligo(dT) 15 primers (Promega). The RT was performed at 421C for 1 h and 1 ml of the cDNA produced (1/25th) was sufficient for one PCR reaction.
The primers used for the subsequent PCRs were as follows:
F3INT ( All adult tissue cDNAs used in Figure 5 were obtained from Origene technologies. Unless otherwise stated PCR cycling parameters following cDNA synthesis were as follows: 941C for 5 min; 35 cycles of 941C for 30 s, 591C for 30 s, 721C for 1 min and 1 cycle of 721C for 5 min (reaction contents described above). Approximately 10 ml of each RT-PCR was run on a 2% agarose gel, transferred onto Hybond N + membrane (Amersham Pharmacia Biotech) and hybridized according to standard Southern blotting protocols (Sambrook et al., 1989) . Selected PCR products were also cloned into pGEM-T easy vector system according to the manufacturer's instructions (Promega). Primer pair F3INT and I22REV (in intron 21) (5 0 -CAAATTCAGCTGCACCAGTGC-3 0 ) were also used to amplify exon 21/flanking genomic DNA for sequencing (Figure 7b ).
Generation of probes for RT-PCR blots
The PTH-B1 coding sequence (76-2530 bp of NM_014451) was amplified by PCR from foetal kidney cDNA using Expandt Long template PCR system (Roche) according to the manufacturer's instructions. Primer pair NF1 (in exon 2) (5 0 -GCTTTATGGGATACCTAAGG-3 0 ) and NR3 primers were used. PCR cycling parameters were as follows: six cycles of 941C for 15 s, 611C (decreasing at 11C per cycle) for 30 s, 721C for 2 min; 10 cycles of 941C for 15 s, 551C for 30 s, 721C for 2 min; 20 cycles of 941C for 15 s, 551C for 30 s, 721C for 2 min (increasing 20 s per cycle); one cycle of 721C for 5 min. PCR products were gel-purified and cloned into PGEM-T easy vector system according to the manufacturer's instructions (Promega). Fragments were also 32 P-dCTP labelled and used to hybridize to PTH-B1 and isoforms 1 and 2 filters as previously described above. IMAGE clone 2230109 (AI624582) was digested with NotI/EcoRI and the resulting 1.8 kb band was resolved on a 0.8% agarose gel, extracted and 32 P-dCTP labelled as described above. This probe was used to hybridize to isoforms 5 and 6 RT-PCR filters (as described above).
